中国飞鹤：期待库存去化完成后经营步入正轨-20260327

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 4.56 [6][4]. Core Insights - The company reported a revenue of RMB 18.11 billion and a net profit attributable to the parent of RMB 1.94 billion for the year 2025, representing a year-on-year decline of 12.7% and 45.7% respectively. The performance was below expectations, as the prior forecast anticipated a revenue decline of only 4.0% and a net profit decline of 14.8% [1]. - The company is currently undergoing a channel inventory clearance, which has led to a temporary decline in revenue. However, it is expected that operations will return to normal after the inventory is cleared, with positive impacts anticipated from fertility subsidies [1][2]. - The gross margin for 2025 decreased by 1.3 percentage points to 65.0%, while the net profit margin fell by 6.5 percentage points to 10.7%. The decline in profitability was primarily due to reduced government subsidies and losses from inventory devaluation [3]. Revenue and Profitability - The revenue from the dairy products and nutrition segment decreased by 12.6% year-on-year to RMB 18.00 billion, while the raw milk business saw a decline of 27.3% to RMB 1.1 billion. The second half of 2025 also reflected a similar trend with a 15.9% and 9.7% decline respectively [2]. - The company’s gross margin for infant formula increased by 2.2 percentage points to 73.5% in 2025, but overall gross margin was impacted by a higher proportion of lower-margin products sold [3]. Forecast and Valuation - The revenue forecast for 2026 and 2027 has been adjusted downwards to RMB 18.84 billion and RMB 19.51 billion, reflecting a decrease of 11% and 12% from previous estimates. The expected net profit for these years is RMB 2.77 billion and RMB 3.01 billion, which is a reduction of 24% and 27% respectively [4]. - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be RMB 0.31, RMB 0.33, and RMB 0.35 respectively, with a price-to-earnings (PE) ratio of 13x applied to the 2026 earnings to derive the target price [4][10].